Patents Represented by Attorney, Agent or Law Firm Medlen & Carroll, LLP
-
Patent number: 7962204Abstract: A method and system for utilizing neurophysiologic information obtained by techniques such as quantitative electroencephalography (QEEG), electrode recordings, MRI in appropriately matching patients with therapeutic entities is disclosed. The present invention enables utilization of neurophysiologic information, notwithstanding its weak correlation with extant diagnostic schemes for mental disorders, for safer and expeditious treatment for mental disorders, discovering new applications for therapeutic entities, improved testing of candidate therapeutic entities, inferring the presence or absence of a desirable response to a treatment, and deducing the mode of action of one or more therapeutic entities. In particular, methods for effectively comparing neurophysiologic information relative to a reference set are disclosed along with database-based tools for deducing therapeutic entity actions on particular patients such that these tools are readily accessible to remote users.Type: GrantFiled: November 18, 2008Date of Patent: June 14, 2011Assignee: CNS Response, Inc.Inventors: Stephen C. Suffin, W. Hamlin Emory, Leonard J. Brandt
-
Patent number: 7951384Abstract: The present invention discloses the method of making and using a novel, non-infective, paramyxovirus vaccine. Paramyxovirus structural proteins within a virus-like particle (VLP) comprise one example of such a vaccine. It is observed that the presence of matrix protein, alone, is sufficient and necessary to provide an effective VLP release. Co-expression of four paramyxovirus structural proteins, however, result in the release of non-infective VLPs with densities and efficiencies of release similar to that of infective particles. Representative diseases wherein a VLP vaccine might be useful include, but are not limited to, Newcastle disease, measles, respiratory syncytial virus infection, and parainfluenza 3 virus infection.Type: GrantFiled: August 2, 2006Date of Patent: May 31, 2011Assignee: University of MassachusettsInventors: Trudy Morrison, Homer D. Pantua
-
Patent number: 7946525Abstract: The invention relates to a material for absorbing noise in aircraft, comprising at least one barrier layer and at least one absorptive layer. The barrier layer is provided with an elastomeric material having a minimum specific density of 1 and a mass per unit area of 1.3 kg/m2 or less while the absorptive layer is equipped with a porous and/or open-cell material having a weight per volume of 4 to 50 kg/m3, preferably 10 to 40 kg/m3, more preferably 15 to 35 kg/m3 even more preferably 20 to 30 kg/m3. The mass per unit area of the sound-absorbing material amounts to 2 kg/m2 or less.Type: GrantFiled: April 28, 2006Date of Patent: May 24, 2011Assignee: Lufthansa Technik AGInventor: Malte Gröning
-
Patent number: 7939340Abstract: The invention relates to compositions, kits and methods used in hydroxyl radical detection. In some embodiments, the invention relates to compositions comprising a dye preferably methylene blue immobilized on a substrate. In additional embodiments, the invention relates methods of correlating color changes of a dye to the presence or absence of hydroxyl radicals. In some embodiments, the invention relates to a methylene blue dye containing test strip and its use in a method for detecting the presence of hydroxyl radicals.Type: GrantFiled: June 28, 2006Date of Patent: May 10, 2011Assignee: Board Of Trustees Of Michigan State UniversityInventors: Andrea Yuki Satoh, Susan J. Masten, James Trosko
-
Patent number: 7932433Abstract: Cyclopropane fatty acid synthase genes and polypeptides are described. Plants are transformed with such genes to produce such polypeptides.Type: GrantFiled: October 7, 2008Date of Patent: April 26, 2011Assignee: Board of Trustees of Michigan State UniversityInventors: Xiaoming Bao, John B. Ohlrogge, Michael R. Pollard
-
Patent number: 7925444Abstract: The present invention provides systems and methods that utilize an information architecture for disambiguating scientific names and other classification labels and the entities to which those names are applied, as well as a means of accessing data on those entities in a networked environment using persistent, unique identifiers.Type: GrantFiled: January 16, 2004Date of Patent: April 12, 2011Assignee: Board of Trustees of Michigan State UniversityInventors: George Garrity, Catherine Lyons
-
Patent number: 7915480Abstract: Disclosed are genetic constructs, transgenic plant cells and transgenic plants, as well as associated methods, for increasing oil production in a plant using F-box gene sequences.Type: GrantFiled: October 30, 2009Date of Patent: March 29, 2011Assignee: Board of Trustees of Michigan State UniversityInventors: John B. Ohlrogge, Sari A. Ruuska, Yonghua Li
-
Patent number: 7901945Abstract: A system and method for recognition of images may include the use of alignment markers. The image recognized may be a pattern from an array, a character, a number, a shape, and/or irregular shapes. The pattern may be formed by elements in an array such as an identification marking and/or a sensor array. More particularly, the system and method relate to discriminating between images by accounting for the orientation of the image. The size and/or location of alignment markers may provide information about the orientation of an image. Information about the orientation of an image may reduce false recognitions. The system and method of image recognition may be used with identification markings, biosensors, micro-fluidic arrays, and/or optical character recognition systems.Type: GrantFiled: July 16, 2008Date of Patent: March 8, 2011Assignee: Board of Regents the University of Texas SystemInventors: Jason E. Meiring, Timothy B. Michaelson, C. Grant Willson
-
Patent number: 7897572Abstract: The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying ?-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.Type: GrantFiled: December 21, 2006Date of Patent: March 1, 2011Assignee: University Of Massachusetts Medical SchoolInventors: Roger J. Davis, Anja Jaeschke
-
Patent number: 7897335Abstract: This invention relates to non-radioactive markers that facilitate the detection and analysis of nascent proteins translated within cellular or cell-free translation systems. Nascent proteins containing these markers can be rapidly and efficiently detected, isolated and analyzed without the handling and disposal problems associated with radioactive reagents. Preferred markers are dipyrrometheneboron difluoride (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) dyes.Type: GrantFiled: June 18, 2002Date of Patent: March 1, 2011Assignee: Ambergen, Inc.Inventors: Kenneth J. Rothschild, Sadanand Gite, Jerzy Olejnik
-
Patent number: 7892739Abstract: The invention relates to stretch measurements of nucleic acids and correlating those measurements to the extent of double- and single-stranded content of a nucleic acid of interest, and to compositions, systems, and devices related thereto. In preferred embodiments, one performs the stretch or elasticity measurements under conditions such that one can determine a nucleic acid sequence or the presence of an oligonucleotide in a sample.Type: GrantFiled: March 27, 2008Date of Patent: February 22, 2011Assignee: Lehigh UniversityInventor: Dmitri Vezenov
-
Patent number: 7868156Abstract: The present invention relates to novel seed specific promoter regions. The present invention further provide methods of producing proteins and other products of interest and methods of controlling expression of nucleic acid sequences of interest using the seed specific promoter regions. The present invention also provides methods of identifying and isolating novel seed specific promoters.Type: GrantFiled: July 14, 2008Date of Patent: January 11, 2011Assignee: Board of Trustees of Michigan State UniversityInventors: John B. Ohlrogge, Christoph Benning, Hongbo Gao, Thomas Arno Alfred Girke, Joseph A. White
-
Patent number: 7863594Abstract: An objective of the present invention is to provide a switching device that shows two markedly different stable resistance characteristics reversibly and repetitively, and which is applicable to highly integrated nonvolatile memories.Type: GrantFiled: August 8, 2006Date of Patent: January 4, 2011Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Hiroyuki Akinaga, Shuichiro Yasuda, Isao Inoue, Hidenori Takagi
-
Patent number: 7858808Abstract: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-?B as well as potent activity against the Gram (+) bacterium B. subtillus and B. cereus with MIC values in the range of 50 ?m/mL.Type: GrantFiled: January 26, 2010Date of Patent: December 28, 2010Assignee: Board of Trustees of Michigan State UniversityInventors: Jetze J. Tepe, Satyamaheshwar Peddibhotla
-
Patent number: 7846655Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.Type: GrantFiled: November 3, 2004Date of Patent: December 7, 2010Assignee: Diagnostic Hybrids, Inc.Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
-
Patent number: 7837992Abstract: A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous activation during fibrinolysis. C1-inhibitor complexes with tcM5. The effect of C1-inhibitor on fibrinolysis and fibrinogenolysis by M5 was determined. Supplemental C1-inhibitor restores the stability of M5 but not that of prouPA. Clot lysis by M5 with supplemental C1-inhibitor showed no attenuation of the rate of fibrinolysis, whereas fibrinogenolysis was prevented by C1-inhibitor. Due to higher dose tolerance of M5 with C1-inhibitor, the rate of fibrin-specific lysis reached that achievable by nonspecific fibrinolysis without inhibitor. Plasma C1-inhibitor stabilized M5 in plasma by inhibiting tcM5 and thereby non-specific plasminogen activation. At the same time, fibrin-specific plasminogen activation remained unimpaired. This unusual dissociation of effects has significant implications for improving the safety and efficacy of fibrinolysis.Type: GrantFiled: April 4, 2007Date of Patent: November 23, 2010Assignee: Beth Israel Deaconess Medical CenterInventors: Victor Gurewich, Ralph Pannell
-
Patent number: 7838502Abstract: The present invention discloses novel signaling pathways controlling the pathogenesis of the human respiratory bacterium, Haemophilus influenzae. The lipooligosaccharide-phosphorylycholine (LOS-PC) cell surface epitope of H. influenzae enhances pathogenesis but also increases bacterial susceptibility to innate and adaptive immunity and the administration of therapeutic compounds. Modulation of the LOS-PC epitope may be affected by an interaction between environmental conditions (i.e., for example, oxygen tension) and genetic regulation of precursor biosynthetic pathway activity. LOS-PC epitope display increases under microaerobic conditions and decreases under aerobic conditions. This is consisent with a bacteria's propensity to initiate pathogensis under low oxygen conditions. Pathogenesis may be prevented by disrupting the role of the putative H. influenzae homologue of CsrA, that downregulates galU expression. Disrupting CsrA repression of galU expression resulted in increased LOS-PC epitope display.Type: GrantFiled: May 6, 2005Date of Patent: November 23, 2010Assignee: University of Massachusetts Medical SchoolInventors: Brian J. Akerley, Sandy M. Wong
-
Patent number: 7824680Abstract: The invention provides methods for detecting and inhibiting angiogenesis, endothelial cell adhesion, and endothelial cell migration using agents which inhibit the specific binding of integrin ?4?1 to one or more of its ligands. The invention further provides methods for screening test compounds for their ability to inhibit angiogenesis, endothelial cell adhesion, or endothelial cell migration by employing agents which inhibit the specific binding of integrin ?4?1 to one or more of its ligands. The invention additionally relates to methods for isolating endothelial progenitor cells which express integrin ?4?1. The methods of the invention are useful in, for example, diagnosing and inhibiting pathological conditions that are associated with angiogenesis, endothelial cell adhesion, and/or endothelial cell migration.Type: GrantFiled: August 1, 2002Date of Patent: November 2, 2010Assignee: The Regents of the University of CaliforniaInventor: Judith A. Varner
-
Patent number: 7820441Abstract: The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.Type: GrantFiled: September 21, 2001Date of Patent: October 26, 2010Assignee: The Regents of the University of MichiganInventors: Jeffrey S. Chamberlain, Dennis J. Hartigan-O'Connor
-
Patent number: 7820628Abstract: The present invention discloses that an intratumoral injection of: i) glycolipids with ?-gal epitope; ii) gene vectors comprising an ?1,3galactosyltransferase gene; or iii) a mixture of ?1,3galactosyltransferase, neuraminidase, and uridine diphosphate galactose results in tumor regression and/or destruction. Binding of the natural anti-Gal antibody to de novo expressed tumoral ?-gal epitopes induces inflammation resulting in an anti-Gal antibody mediated opsonization of tumor cells and their uptake by antigen presenting cells. These antigen presenting cells migrate to draining lymph nodes and activate tumor specific T cells thereby converting the treated tumor lesions into in situ autologous tumor vaccines. This therapy can be applied to patients with multiple lesions and in neo-adjuvant therapy to patients before tumor resection.Type: GrantFiled: February 16, 2006Date of Patent: October 26, 2010Assignee: University of Massachusetts Medical SchoolInventor: Uri Galili